Chronic Leukemia

Chronic Leukemia News

  • Rituximab Maintenance a 'Relevant' Option in Elderly CLL Patients Two-years of rituximab maintenance therapy can prolong remission in selected elderly patients with chronic lymphocytic leukemia (CLL) in first remission after an abbreviated front-line course of fludarabine, cyclophosphamide and rituximab (FCR), according to a study from France.
  • ASH Venetoclax and Rituximab: New Standard of Care in CLL? The new combination of venetoclax and rituximab was superior to the standard-of-care combination of bendamustine and rituximab in the treatment of relapsed/refractory CLL.

Chronic Leukemia Perspective